Historical Information | Lisata Therapeutics, Inc.

Caladrius Biosciences News Releases

Year

Mar 13, 2017

Caladrius Biosciences to Host 2016 Fourth Quarter and Full Year Financial Results Conference Call on March 17, 2017 at 8:30 am Eastern Time

BASKING RIDGE, N.J., Mar. 13, 2017 — Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company combining a select therapeutic development pipeline with an industry-leading development and manufacturing services provider (PCT), announces today that the Company

Mar 02, 2017

Caladrius Biosciences to Present at Upcoming March Conferences

BASKING RIDGE, N.J., Mar. 2, 2017 — Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company combining a select therapeutic development pipeline with an industry-leading development and manufacturing services provider (PCT), announces today that the Company’s

Feb 23, 2017

Caladrius Biosciences Awarded $12.2 Million Grant from CIRM in Support of Phase 2 Clinical Trial of CLBS03 to Treat Type 1 Diabetes

BASKING RIDGE, N.J., Feb. 23, 2017 – Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company combining a select therapeutic development pipeline with an industry-leading development and manufacturing services provider (PCT), announces today that the

Feb 01, 2017

Caladrius Biosciences to Present at Upcoming February Conferences

BASKING RIDGE, N.J., Feb. 1, 2017 — Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company combining a select therapeutic development pipeline with an industry-leading development and manufacturing services provider (PCT), announces today that the Company’s

Jan 25, 2017

Caladrius Biosciences Announces Addition of Three Clinical Sites, Including University of California, San Francisco, for the Ongoing Phase 2 Study of CLBS03 in T1D

BASKING RIDGE, N.J., Jan. 25, 2017 — Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company combining a select therapeutic development pipeline with an industry-leading development and manufacturing services provider (PCT), announces today that three

Jan 06, 2017

Caladrius Biosciences Updates Status of Receipt of Funds for a Portion of Previously Announced Private Placement

BASKING RIDGE, N.J., Jan. 6, 2017 — Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company combining a select therapeutic development pipeline with an industry-leading development and manufacturing services provider (PCT), announced today that $6 million

Jan 03, 2017

Caladrius Biosciences to Present at Upcoming January Conferences

BASKING RIDGE, N.J., Jan. 3, 2017 — Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company combining a select therapeutic development pipeline with an industry-leading development and manufacturing services provider (PCT), announces today that the PCT’s

First page
Previous page
Page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Current page 8

Displaying 71 - 77 of 77

Cend Therapeutics News Releases

Jul 06, 2022

PDF Version

Cend Therapeutics Announces Publication of Pancreatic Cancer Trial Data in the Lancet Gastroenterology and Hepatology

Peer-reviewed study data suggest CEND-1, in combination with gemcitabine and nab-paclitaxel, demonstrates favorable safety and tolerability along with encouraging efficacy SAN DIEGO, July 06, 2022 (GLOBE NEWSWIRE) -- Cend Therapeutics, Inc. (“Cend”), a privately-held, clinical-stage drug discovery

Jun 29, 2022

PDF Version

Cend Therapeutics’ CEND-1 Granted Fast Track Designation for Pancreatic Cancer

SAN DIEGO, June 29, 2021 (GLOBE NEWSWIRE) -- The US Food and Drug Administration (FDA) has granted Fast Track Development (FTD) status for Cend’s investigational drug, CEND-1, for the first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) in combination with

Jun 09, 2022

PDF Version

Cend Therapeutics Announces First Patient Treated in Phase 2b Trial of CEND-1 led by Australasian Gastro-Intestinal Trials Group

SAN DIEGO, June 09, 2022 (GLOBE NEWSWIRE) -- Cend Therapeutics, Inc. (“Cend”) today announced that the first patient has been treated in the Phase 2b study of CEND-1, Cend’s lead investigational drug, in patients with first-line metastatic pancreatic ductal adenocarcinoma.

Apr 27, 2022

PDF Version

Caladrius Biosciences and Cend Therapeutics Announce Definitive Merger Agreement

Combined company to be renamed Lisata Therapeutics upon transaction closing Combination will create a financially sound Nasdaq-listed company with a diverse product development pipeline, strong existing partnerships and potential for future attractive partnerships Lisata to combine development

Nov 16, 2021

PDF Version

Cend Therapeutics Announces First Patient Dosing in Clinical Trial of CEND-1 for the Treatment of Selected Gastrointestinal Cancers

SAN DIEGO, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Patient dosing has begun in a Phase 1b/2a clinical trial to evaluate the safety, tolerability and pharmacologic activity of CEND-1 in pancreatic, appendiceal and colon cancers in collaboration with the University of Kansas Cancer Center (KUCC).

Feb 16, 2021

PDF Version

Cend Therapeutics and Qilu Pharmaceutical Announce Partnership

SAN DIEGO and JINAN, China, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Cend Therapeutics, Inc. , a clinical-stage biotech company, and Qilu Pharmaceutical , a major Chinese pharmaceutical company, announced today that the companies have entered a Collaboration and License Agreement to develop and

Sep 21, 2020

PDF Version

Cend Therapeutics Announces Acquisition of Impilo Therapeutics

SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Cend Therapeutics, Inc. , a clinical-stage biotech company, announced today that it has acquired Impilo Therapeutics, Inc. The combination expands Cend’s drug delivery capabilities to create a unique platform for targeted tissue penetrating delivery of

Sep 15, 2020

PDF Version

Cend Therapeutics Announces Presentation and Abstract Publication at 2020 European Society for Medical Oncology (ESMO) Meeting

SAN DIEGO, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Cend Therapeutics, Inc. , a clinical-stage biotech company, announced the publication of its abstract on the website of the annual meeting of the European Society for Medical Oncology. The poster that includes the detailed results will be presented at

Jul 08, 2020

PDF Version

CEND Therapeutics Announces Board Member David Slack Will Succeed Erkki Ruoshlahti as President & CEO

LA JOLLA, Calif., July 08, 2020 (GLOBE NEWSWIRE) -- Cend Therapeutics, Inc. (formerly DrugCendR, Inc.), a clinical-stage biotech company, announced today changes in the senior management of the company. David Slack, MBA will take over as President and CEO.

Aug 20, 2019

PDF Version

DrugCendR Inc. Announces the Appointment of Dr. Daniel Von Hoff as Clinical Advisor

LA JOLLA, Calif., Aug. 20, 2019 (GLOBE NEWSWIRE) -- DrugCendR, Inc., a clinical-stage biotech company developing next generation therapies for the treatment of solid tumors, today announced that Dr. Daniel Von Hoff will be a clinical advisor to the company. In this role, Dr.

Current page 1
Page 2
Next page
Last page